Electroconvulsive therapy decreases dopamine D2 receptor binding in the anterior cingulate in patients with depression: A controlled study using positron emission tomography with radioligand [11C]FLB 457

Journal of Clinical Psychiatry

Volumn 71, Issue 6, 2010, Pages 793-799

  Saijo, Tomoyuki ^a,b,c   Takano, Akihiro ^b   Suhara, Tetsuya ^b   Arakawa, Ryosuke ^a,b   Okumura, Masaki ^a,b   Ichimiya, Tetsuya ^a,c   Ito, Hiroshi ^b   Okubo, Yoshiro ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^c Asai Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; FLUVOXAMINE; ISOREMOXIPRIDE; PAROXETINE;

ADULT; ARTICLE; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROCONVULSIVE THERAPY; FEMALE; HUMAN; JAPAN; MAJOR DEPRESSION; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT RESPONSE; VOXEL BASED MORPHOMETRY;

ADULT; CARBON RADIOISOTOPES; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOPAMINE ANTAGONISTS; ELECTROCONVULSIVE THERAPY; FEMALE; FUNCTIONAL LATERALITY; GYRUS CINGULI; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PYRROLIDINES; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2; SALICYLAMIDES; TREATMENT OUTCOME;

EID: 77953800530     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04746blu     Document Type: Article

References (60)

1. American Psychiatric Association Committee on Electroconvulsive Therapy. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging, Second Edition. Washington, DC: American Psychiatric Association; 2001.
2. Nutt DJ. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry. 2008;69(suppl E1):4-7.
3. Sanacora G, Mason GF, Rothman DL, et al. Increased cortical GABA concentrations in depressed patients receiving ECT. Am J Psychiatry. 2003;160(3):577-579. (Pubitemid 41094271)
4. Browning SM, Cowen PJ. Changes in mood, appetite and psychomotor retardation in depressed patients given ECT. Br J Psychiatry. 1986;149:371-373.
5. Cowen PJ, Nutt DJ, Green AR. Enhanced 5-hydroxytryptamine and dopamine-mediated behavioural responses following convulsions, pt 2:. the effects of anaesthesia and current conditions on the appearance of enhanced responses following electroconvulsive shock. Neuropharmacology. 1980;19(9):901-906.
6. Berrios GE, Canagasabey AF. Depression, eye blink rate, psychomotor retardation, and electroconvulsive therapy-enhanced dopamine receptor sensitivity. Convuls Ther. 1990;6(3):224-230.
7. Glue P, Costello MJ, Pert A, et al. Regional neurotransmitter responses after acute and chronic electroconvulsive shock. Psychopharmacology (Berl). 1990;100(1):60-65. (Pubitemid 20015672)
8. Yoshida K, Higuchi H, Kamata M, et al. Single and repeated electroconvulsive shocks activate dopaminergic and 5-hydroxytryptaminergic neurotransmission in the frontal cortex of rats. Prog Neuropsychopharmacol Biol Psychiatry. 1998;22(2):435-444.
9. Hoffmann G, Linkowski P, Kerkhofs M, et al. Effects of ECT on sleep and CSF biogenic amines in affective illness. Psychiatry Res. 1985;16(3):199-206. (Pubitemid 16208253)
10. 2-like dopamine receptors. Psychopharmacology (Berl). 1997;133(1):77-84.
11. Zarrindast MR, Sahebgharani M, Burnham WM. The effect of electroconvulsive shock seizures on behaviour induced by dopaminergic agonists and on immobility in the Porsolt test. Eur Neuropsychopharmacol. 2004;14(6):509-514. (Pubitemid 39626900)
12. Barkai AI, Durkin M, Nelson HD. Localized alterations of dopamine receptor binding in rat brain by repeated electroconvulsive shock: an autoradiographic study. Brain Res. 1990;529(1-2):208-213. (Pubitemid 20326858)
13. 2 receptors: a potential pharmacological target for nomifensine and tranylcypromine but not other antidepressant treatments. Pharmacol Biochem Behav. 1995;51(4):565-569.
14. 18F]setoperone. Biol Psychiatry. 2005;57(9):1004-1010.
15. Nobler MS, Oquendo MA, Kegeles LS, et al. Decreased regional brain metabolism after ECT. Am J Psychiatry. 2001;158(2):305-308.
16. 2 receptor in depression. Eur Neuropsychopharmacol. 2001;11(3):215-220.
17. Tomkins DM, Sellers EM. Addiction and the brain: the role of neurotransmitters in the cause and treatment of drug dependence. CMAJ. 2001;164(6):817-821.
18. 11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain. J Cereb Blood Flow Metab. 1999;19(10):1164-1173.
19. 11C]FLB 457 binding in extrastriatal regions. Nucl Med Commun. 2001;22(11):1215-1221.
20. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994:32.
22. 2 dopamine receptors. J Nucl Med. 1995;36(7):1275-1281.
23. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4(3 pt 1):153-158. (Pubitemid 27024284)
24. Gunn RN, Lammertsma AA, Hume SP, et al. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage. 1997;6(4):279-287.
25. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27(9):1533-1539.
26. 2 receptor density and affinity in the human brain measured by 3D PET. Int J Neuropsychopharmacol. 1999;2(2):73-82.
27. Friston KJ, Holmes AP, Worsley KJ. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp. 1995;2(4):189-210.
28. Meyer JH, Gunn RN, Myers R, et al. Assessment of spatial normalization of PET ligand images using ligand-specific templates. Neuroimage. 1999;9(5):545-553.
29. Lacadie CM, Fulbright RK, Rajeevan N, et al. More accurate Talairach coordinates for neuroimaging using non-linear registration. Neuroimage. 2008;42(2):717-725.
30. Talairach JTP. Co-Planar Stereotaxic Atlas of the Human Brain: 3-Dimensional Proportional System: An Approach to Cerebral Imaging. New York, NY: Thieme Medical Publishers; 1988.
31. 11C]FLB 457 binding measured by PET. Synapse. 2001;41(2):87-95.
32. 11C]raclopride in man. Synapse. 1995;20(3):200-208.
33. Laruelle M. Dopamine transmission in the schizophrenic brain. In: Hirsh S, Weinberger D, eds. Schizophrenia: Part Two, Biological Aspects. Oxford, United Kingdom: Blackwell Publishing; 2003:365-387.
34. Devanand DP, Dwork AJ, Hutchinson ER, et al. Does ECT alter brain structure? Am J Psychiatry. 1994;151(7):957-970.
35. Devinsky O, Morrell MJ, Vogt BA. Contributions of anterior cingulate cortex to behaviour. Brain. 1995;118(pt 1):279-306.
36. Wayment HK, Schenk JO, Sorg BA. Characterization of extracellular dopamine clearance in the medial prefrontal cortex: role of monoamine uptake and monoamine oxidase inhibition. J Neurosci. 2001;21(1):35-44.
37. 2 dopamine receptors as a function of aging and chronic reserpine treatment following irreversible modification: a key to receptor regulatory mechanisms. J Neurosci. 1987;7(5):1484-1491.
38. 3 receptors by chronic drug treatments. J Pharmacol Exp Ther. 2000;295(3):1232-1240.
39. Mega MS, Cummings JL, Salloway S, et al. The limbic system: an anatomic, phylogenetic, and clinical perspective. J Neuropsychiatry Clin Neurosci. 1997;9(3):315-330.
40. Pizzagalli D, Pascual-Marqui RD, Nitschke JB, et al. Anterior cingulate activity as a predictor of degree of treatment response in major depression: evidence from brain electrical tomography analysis. Am J Psychiatry. 2001;158(3):405-415.
41. Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diag nosis and optimised treatment. Br Med Bull. 2003;65(1):193-207.
42. Drevets WC. Prefrontal cortical-amygdalar metabolism in major depression. Ann N Y Acad Sci. 1999;877:614-637.
43. Marano CM, Phatak P, Vemulapalli UR, et al. Increased plasma concentration of brain-derived neurotrophic factor with electroconvulsive therapy: a pilot study in patients with major depression. J Clin Psychiatry. 2007;68(4):512-517.
44. 2 receptors in depression measured with single photon emission computed tomography. Biol Psychiatry. 1994;35(2):128-132.
45. 2 binding in depression. Psychol Med. 1997;27(6):1247-1256.
46. Klimek V, Schenck JE, Han H, et al. Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol Psychiatry. 2002;52(7):740-748.
47. Parsey RV, Oquendo MA, Zea-Ponce Y, et al. Dopamine D(2) receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol Psychiatry. 2001;50(5):313-322. (Pubitemid 32816943)
48. 11C]raclopride binding and cognitive function in patients with depression. J Affect Disord. 2006;95(1-3):35-42.
49. 11C]raclopride. J Affect Disord. 2007;101(1-3):113-122.
50. 2 receptor density and affinity in the human brain using PET. Neuroimage. 2004;22(2):794-803.
51. Takano H, Motohashi N, Uema T, et al. Changes in regional cerebral blood flow during acute electroconvulsive therapy in patients with depression: positron emission tomographic study. Br J Psychiatry. 2007;190:63-68. (Pubitemid 46121503)
52. Bench CJ, Friston KJ, Brown RG, et al. The anatomy of melancholia: focal abnormalities of cerebral blood flow in major depression. Psychol Med. 1992;22(3):607-615.
53. Shah SA, Doraiswamy PM, Husain MM, et al. Posterior fossa abnormalities in major depression: a controlled magnetic resonance imaging study. Acta Psychiatr Scand. 1992;85(6):474-479.
54. 11C]FLB 457 in rat brain: an ex vivo study. Synapse. 2006;59(3):162-172.
55. Alcock SJ, Hemsley KM, Crocker AD. Atropine acts in the ventral striatum to reduce raclopride-induced catalepsy. Eur J Pharmacol. 2001;424(3):179-187.
56. 2 dopamine receptors? Anesth Analg. 1994;79(6):1191-1192.
57. 2 receptors in striatum and anterior cingulate gyrus in major depression. Neuroimage. 1997;5(4, pt 1):251-260.
58. 2 dopamine receptor gene polymorphism: paroxetine and social functioning in posttraumatic stress disorder. Eur Neuropsychopharmacol. 2003;13(5):313-320.
59. Moresco RM, Colombo C, Fazio F, et al. Effects of fluvoxamine treatment on the in vivo binding of [F-18]FESP in drug naive depressed patients: a PET study. Neuroimage. 2000;12(4):452-465.
60. 2 receptors: a pet study on OCD drug-naive patients. Neuropsychopharmacology. 2007;32(1):197-205.